A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

The FDA approved Hikma's first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Diabetes drug Victoza, or liraglutide, is a first generation GLP-1, a class of treatments that has seen overwhelming demand. It has been on the FDA’s shortage list since 2023, and currently ...

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...

Victoza has just given Novo Nordisk a boost, with new data showing it can cut the risk of heart attacks, strokes and cardiovascular death in type 2 diabetes patients. The five-year LEADER study of ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.